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Screen-and-treat for chronic hepatitis B: an overdue issue for 
sub-Saharan Africa
For more than a decade, WHO has focused its eﬀ orts 
against infectious diseases in Africa on HIV, tuberculosis, 
and malaria. HIV beneﬁ ted from unprecedented eﬀ orts 
to enable diagnosis and prevention of transmission and 
to provide therapy at low cost. National networks of 
health clinics, transport of samples, centralised and—
more recently—point-of-care testing, and monitoring 
of antiretroviral treatment (ART) by CD4 counts 
and viral load were put into place. External ﬁ nancial 
support from governments (eg, from the President’s 
Emergency Plan for AIDS Relief and the European 
Union), international funding agencies, and numerous 
charities has allowed roughly 50% of HIV-infected 
people in sub-Saharan Africa to beneﬁ t from ART that 
is more than 90% eﬀ ective.1 In contrast to HIV, and 
as noted in an Article in The Lancet Global Health by 
Maud Lemoine and colleagues,2 little attention is being 
paid to chronic hepatitis B virus (HBV) infection, which 
aﬀ ects 80–100 million people in sub-Saharan Africa 
and is a major cause of mortality from decompensated 
cirrhosis and hepatocellular carcinoma. Lemoine and 
colleagues and others have reported that 5–20%3 of the 
1 billion people living in sub-Saharan Africa are positive 
for hepatitis B surface antigen (HBsAg) and roughly 5% 
of them are at high risk of fatal complications. WHO has 
recently released a set of recommendations addressing 
chronic HBV infection, some of which are adapted to 
the low-income and middle-income countries that 
bear most of the burden.4 HBV infection is usually 
asymptomatic when acquired and remains clinically 
silent until it is too late for eﬀ ective treatment. Lemoine 
and colleagues2 and—in an associated cost-eﬀ ectiveness 
Article in The Lancet Global Health—Shevanthi Nayagam 
and colleagues5 propose and show that it is feasible 
to systematically and aﬀ ordably screen, assess, and 
eﬀ ectively treat chronic HBV infection in a sub-Saharan 
African setting. At present, the only infected but 
asymptomatic individuals identiﬁ ed are blood donors 
who are screened for HBsAg before they can donate. 
These people can then be assessed for chronic HBV 
infection and receive appropriate antiviral treatment. 
However, receipt of such treatment is uncommon 
in sub-Saharan Africa because, although HBsAg 
screening is mandatory, improving the donor’s health is 
considered unaﬀ ordable.6 
Lemoine and colleagues show that, in a relatively large 
population representative of The Gambia, community 
HBsAg screening is feasible and well accepted by 
the population. Once appropriately informed and 
encouraged, individuals consented to be part of an 
eﬀ ective diagnostic process to identify people with 
chronic HBV infection who, although still in good 
health, will probably be able to avoid cirrhosis and 
hepatocellular carcinoma if they can receive prolonged 
antiviral treatment. For departments of health in 
sub-Saharan Africa, especially those in the western 
half where the prevalence of genotype E chronic HBV 
infection is the highest in the world, prevention of HBV-
related liver disease should become a priority, and the 
proposed screen-and-treat strategy should be the object 
of serious governmental consideration.
The main challenge in low-resource countries is cost 
and allocation of resources. Can HBV control in sub-
Saharan Africa be aﬀ ordable beyond the systematic 
vaccination that is already implemented? Nayagam 
and colleagues carefully investigated this cost issue.5 
From a health economist’s viewpoint, a cost of about 
US$511 per quality-adjusted life-year gained or $540 per 
disability-adjusted life-year averted would seem low, 
but these sums are roughly the same as the annual 
income per capita in The Gambia and many other 
countries in sub-Saharan Africa. Most governments in 
sub-Saharan Africa do not support health-care costs 
through insurance systems, although such schemes 
have been initiated in several countries and successful 
in a few. In the next 5–10 years, community ﬁ nancial 
support is unlikely to be available. External funding, 
such as that distributed to control HIV is unlikely to 
be made available, since chronic HBV infection is not 
yet considered a health priority, is not in the eye of the 
media, and is not perceived as important by the public. 
Apparently healthy patients will be reluctant to pay for 
treatment of a disease that will only aﬀ ect them in the 
distant future. Willingness to pay will lie with individuals. 
Most likely, only educated people who are relatively 
better oﬀ  ﬁ nancially will be both willing and able to pay.
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These two Articles on the feasibility of screen-and-
treat interventions for chronic HBV infection in sub-
Saharan Africa have some weaknesses. The strategy 
of combining vaccination with the screen-and-treat 
approach is theoretically suitable for the control of 
chronic HBV infection in sub-Saharan Africa, but will 
lose eﬀ ectiveness due to poor compliance. Data from 
reports on generalised vaccination in sub-Saharan 
Africa suggest that poor adherence is common.7,8 In the 
Article by Lemoine and colleagues, compliance with 
screening was 73–81%, with 81% of HBsAg-positive 
people in the community and 42% of those screened 
at the blood bank subsequently attending a specialist 
clinic for HBV diagnosis and assessment of whether 
antiviral treatment was needed. Individuals in the 
community were reminded about attending the clinic 
up to three times, whereas those at the blood bank 
were not reminded, hence the much poorer compliance. 
Another problem with these studies is the inclusion 
of quantitative HBV DNA assays in the therapeutic 
decision making. These assays are not only expensive 
and technically demanding, but are also unavailable in 
most tertiary hospitals in sub-Saharan Africa and would 
therefore require centralised testing. Experience with 
the deployment of HIV viral load testing has showed 
that the delays created by centralised testing generate 
substantial loss to follow-up.9 Until simple, aﬀ ordable, 
point-of-care HBV DNA testing is available, indication 
for antiviral treatment should rely on simpler and 
less costly criteria such as alanine aminotransferase, 
transient elastography, aspartate aminotransferase-
platelet ratio index, or γ-glutamyl transpeptidase-
platelet ratio index.
The inclusion of chronic HBV infection in health 
priorities is long overdue and these two Articles provide 
evidence of feasibility and potential solutions. This issue 
can no longer be avoided; the ball has started rolling and 
WHO, governments, charities, the media, and the public 
need to embrace the need to tackle HBV infection at 
both the public health and economic level.
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